Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.35)
# 329
Out of 5,182 analysts
236
Total ratings
48.95%
Success rate
19.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $50 → $67 | $23.99 | +179.28% | 10 | Apr 16, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Equal-Weight | $173 → $185 | $128.04 | +44.49% | 33 | Apr 10, 2026 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $13 → $12 | $4.77 | +151.57% | 7 | Apr 8, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $150 → $136 | $85.20 | +59.62% | 15 | Mar 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $201.22 | +12.31% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $69.22 | +32.91% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $13.00 | +7.69% | 5 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $38.62 | +107.15% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $61.60 | +15.26% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $18.06 | -33.55% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $7.20 | +163.89% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $79 | $66.82 | +18.23% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $13.25 | +111.32% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $19.15 | -89.56% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.49 | +645.34% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.30 | +7.62% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $68.85 | +23.46% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $39.51 | -31.66% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.82 | +816.23% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $4.52 | -11.50% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.46 | +173.97% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $5.76 | +143.06% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.76 | +32.98% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.91 | +57.07% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $0.99 | +910.10% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $44.65 | -50.73% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.59 | +1,448.49% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.86 | +6,867.83% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.76 | +59.57% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $9.62 | +6,635.97% | 6 | May 8, 2020 |
Ultragenyx Pharmaceutical
Apr 16, 2026
Maintains: Overweight
Price Target: $50 → $67
Current: $23.99
Upside: +179.28%
Neurocrine Biosciences
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $173 → $185
Current: $128.04
Upside: +44.49%
Bicycle Therapeutics
Apr 8, 2026
Maintains: Equal-Weight
Price Target: $13 → $12
Current: $4.77
Upside: +151.57%
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Overweight
Price Target: $150 → $136
Current: $85.20
Upside: +59.62%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $201.22
Upside: +12.31%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $69.22
Upside: +32.91%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $13.00
Upside: +7.69%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $38.62
Upside: +107.15%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $61.60
Upside: +15.26%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $18.06
Upside: -33.55%
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $7.20
Upside: +163.89%
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $66.82
Upside: +18.23%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $13.25
Upside: +111.32%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $19.15
Upside: -89.56%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.49
Upside: +645.34%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.30
Upside: +7.62%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $68.85
Upside: +23.46%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $39.51
Upside: -31.66%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $3.82
Upside: +816.23%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $4.52
Upside: -11.50%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.46
Upside: +173.97%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $5.76
Upside: +143.06%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.76
Upside: +32.98%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.91
Upside: +57.07%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $0.99
Upside: +910.10%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $44.65
Upside: -50.73%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.59
Upside: +1,448.49%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.86
Upside: +6,867.83%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.76
Upside: +59.57%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $9.62
Upside: +6,635.97%